Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Body mass index \> or = to 25 kg/m2.
HbA1c \> or =7% and \< or =10% at screening.
FPG \> or = 7.0mmol/L (126mg/dL) at visit 2.
Receiving at least 0.85g of metformin at constant dose(s) for at least 8 weeks prior to visit 1a.
Female subjects must be postmenopausal or using effective contraceptive measures.
You may not be if
Use of any other oral antidiabetic drug other than metformin within 12 weeks prior to screening.
Subjects with clinically significant ongoing oedema requiring pharmacological treatment or with a history of oedema requiring pharmacological treatment.
Subjects with a history of severe hypoglycaemia.
Renal disease or renal dysfunction.
Presence of clinically significant hepatic disease.
Presence of unstable or severe angina or known NYHA grade I-IV congestive heart failure.
Subjects who have had a previous myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass graft or cerebrovascular accident within 3 months prior to screening.
